| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Carveol targets the TRPV3 receptor, acting as an agonist. TRPV3 is a member of the transient receptor potential (TRP) family of ion channels, which are involved in sensory perception, including temperature sensation and pain. By activating TRPV3, carveol may modulate calcium influx and cellular signaling pathways. However, its specific binding affinity and selectivity for TRPV3 over other TRP channels have not been fully characterized.
|
|---|---|
| ln Vitro |
Carveol demonstrates in vitro activity as a TRPV3 agonist. It activates TRPV3 channels, leading to calcium influx in cells expressing the receptor. The compound's terpene alcohol structure is characteristic of many natural products with biological activities. However, detailed in vitro activity data, including EC50 values and selectivity profiles, are limited. Carveol is primarily studied for its sensory properties rather than its pharmacological effects.
|
| ln Vivo |
In vivo activity of Carveol is related to its use as a fragrance and flavoring agent. It is a constituent of spearmint essential oil and is generally recognized as safe for use in foods and cosmetics. The compound's activity as a TRPV3 agonist suggests potential applications in pain research, but comprehensive in vivo studies evaluating its pharmacokinetic properties and efficacy are limited. Further research is needed to assess its potential therapeutic applications.
|
| Enzyme Assay |
In vitro receptor binding experiments for Carveol typically involve measuring its activity at TRPV3 receptors. Cells expressing TRPV3 are treated with the compound, and calcium flux is measured using fluorescent indicators. Dose-response curves are generated to determine the compound's potency as a TRPV3 agonist. The compound's chemical properties are characterized using standard analytical methods such as GC and GC-MS. Its purity and identity are confirmed by NMR and other spectroscopic techniques.
|
| Cell Assay |
In vitro cellular experiments for Carveol typically involve studying its effects on cells expressing TRPV3 receptors. Cells are treated with the compound, and calcium influx is measured using fluorescent calcium indicators. The compound's effects on cell viability and proliferation are also assessed. Cytotoxicity assays are performed to ensure that the observed effects are not due to cell death. The compound's activity as a TRPV3 agonist is evaluated in these cellular models.
|
| Animal Protocol |
In vivo animal experiments for Carveol would typically involve administering the compound to rodents via oral gavage, inhalation, or topical application. Pain models could be used to assess the compound's effects as a TRPV3 agonist. However, comprehensive in vivo studies evaluating its pharmacokinetic properties and efficacy are limited. The compound is generally recognized as safe for use in foods and cosmetics.
|
| ADME/Pharmacokinetics |
Metabolism / Metabolites
Carvacrol's known human metabolites include (2S,3S,4S,5R)-3,4,5-trihydroxy-6-(2-methyl-5-prop-1-en-2-ylcyclohex-2-en-1-yl)oxaoxane-2-carboxylic acid. Carvacrol is also known as a human metabolite of (-)-limonene and (+)-limonene. Pharmacokinetic properties of Carveol have not been extensively characterized. With a molecular weight of 152.24 and moderate lipophilicity, the compound is expected to be absorbed from the gastrointestinal tract and distributed throughout the body. It is volatile and can be absorbed through inhalation and skin contact. The compound is metabolized and excreted, but detailed pharmacokinetic studies are limited. It is insoluble in water. |
| Toxicity/Toxicokinetics |
Toxicological data for Carveol indicate that it is generally recognized as safe for use in foods and cosmetics. However, as with all essential oil components, it may cause skin irritation or sensitization in some individuals. The compound is flammable and should be handled with care. Researchers should follow standard safety protocols for handling terpenes and essential oil components.
|
| Additional Infomation |
Carveol is a clear, colorless liquid, insoluble in water. It is a limonene monoterpene compound with the structure cyclohexyl-2-en-1-ol, substituted with a methyl group at position 2 and a prop-1-en-2-yl group at position 5. It is a volatile oil component and a plant metabolite. Carveol has been reported to be found in oregano (Origanum dictamnus), yarrow (Achillea nobilis), and several other organisms with relevant data.
Carveol is a natural product that has not entered clinical trials or received regulatory approval for therapeutic use. It is primarily used as a fragrance ingredient and flavor additive in the food industry. Its activity as a TRPV3 agonist makes it a compound of interest for research on pain and sensory perception. The compound is also known as 2-Methyl-5-isopropenyl-2-cyclohexen-1-ol. Further research is needed to explore its potential therapeutic applications. |
| Molecular Formula |
C10H16O
|
|---|---|
| Molecular Weight |
152.2334
|
| Exact Mass |
152.12
|
| CAS # |
99-48-9
|
| PubChem CID |
7438
|
| Appearance |
Colorless to light yellow liquid
|
| Density |
0.9±0.1 g/cm3
|
| Boiling Point |
231.5±40.0 °C at 760 mmHg
|
| Melting Point |
208 °F (NTP, 1992)
|
| Flash Point |
98.3±0.0 °C
|
| Vapour Pressure |
0.0±1.0 mmHg at 25°C
|
| Index of Refraction |
1.498
|
| LogP |
2.55
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
11
|
| Complexity |
191
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O([H])C1([H])C(C([H])([H])[H])=C([H])C([H])([H])C([H])(C(=C([H])[H])C([H])([H])[H])C1([H])[H]
|
| InChi Key |
BAVONGHXFVOKBV-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C10H16O/c1-7(2)9-5-4-8(3)10(11)6-9/h4,9-11H,1,5-6H2,2-3H3
|
| Chemical Name |
2-methyl-5-prop-1-en-2-ylcyclohex-2-en-1-ol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~656.90 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (16.42 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (16.42 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (16.42 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.5690 mL | 32.8450 mL | 65.6901 mL | |
| 5 mM | 1.3138 mL | 6.5690 mL | 13.1380 mL | |
| 10 mM | 0.6569 mL | 3.2845 mL | 6.5690 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
